FDA Approves Two New Cancer Drugs, But One Comes With a Sticker Shock

The FDA greenlit two significant cancer treatments in the past 24 hours, marking a major weekend for oncology. The headline grabber is Rasonque (daraxonrasib) from Revolution Medicines, the first-ever RAS inhibitor approved for metastatic pancreatic cancer—a notoriously tough-to-treat disease with a dismal 13% five-year survival rate. In trials, the drug doubled overall survival to 13.2 months compared to standard chemotherapy, cutting the risk of death by roughly...